CPT® Code 84234

1. Indications

The progesterone receptor assay (CPT® Code 84234) is indicated for the evaluation of breast cancer tissue to determine the presence of progesterone receptors. This assay is particularly relevant in the following scenarios:

• Breast Cancer Diagnosis The assay is performed on patients diagnosed with breast cancer to assess the hormone receptor status, which is critical for treatment planning.
• Treatment Decision-Making The results of the assay help oncologists decide whether hormone therapy is a viable treatment option based on the receptor status of the tumor.
• Prognostic Assessment The presence or absence of progesterone receptors can provide prognostic information regarding the likely behavior of the cancer and its response to therapy.

2. Procedure

The procedure for conducting a progesterone receptor assay involves several key steps to ensure accurate results. Each step is crucial for the proper evaluation of the breast cancer tissue.

• Step 1: Sample Collection A sample of breast cancer tissue is obtained, typically through a biopsy or surgical resection. This tissue sample is essential for the assay, as it provides the necessary material to analyze the presence of progesterone receptors.
• Step 2: Tissue Preparation The collected tissue sample is then processed in the laboratory. This involves fixing the tissue in formalin and embedding it in paraffin to preserve the cellular structure and allow for sectioning.
• Step 3: Sectioning Thin sections of the prepared tissue are cut using a microtome. These sections are placed on slides for further analysis. The thickness of the sections is critical to ensure that the assay can accurately detect the presence of hormone receptors.
• Step 4: Staining The tissue sections are subjected to immunohistochemical staining, which involves applying antibodies that specifically bind to progesterone receptors. This step is vital for visualizing the receptors under a microscope.
• Step 5: Microscopic Examination A pathologist examines the stained slides under a microscope to determine the presence and quantity of progesterone receptors in the tumor cells. The results are then documented and interpreted to guide treatment decisions.

3. Post-Procedure

After the progesterone receptor assay is completed, the results are typically available within a few days. The pathologist will provide a report detailing the receptor status, which is crucial for the oncologist in formulating a treatment plan. If the tumor is found to be progesterone receptor positive, hormone therapy may be considered as part of the treatment regimen. Patients may be monitored for any side effects or responses to therapy, and follow-up appointments will be scheduled to assess the effectiveness of the treatment. Additionally, the results of the assay may influence further diagnostic testing or imaging studies to evaluate the extent of the disease.